UroGen Pharma Ltd

NASDAQ:URGN  
5.44
+0.27 (+5.22%)
Other Pre-Announcement

UroGen Pharma Reports Q4 Loss Per Share Of $1.27

Published: 03/21/2022 12:53 GMT
UroGen Pharma Ltd (URGN) - Urogen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Corporate Developments.
Q4 Loss per Share $1.27.
Net Product Revenue of Jelmyto for Q4 2021 of $16.2 Million.
Urogen Pharma - As of Dec 31, 2021, Cash, Equivalents, Marketable Securities Totaled $89.8 Million, Does Not Include First Tranche of Term Loan Facility.
Anticipates Full Year 2022 Net Product Revenues From Jelmyto to Be in Range of $70 to $80 Million.
Q4 Earnings per Share View $-1.18, Revenue View $16.5 Million -- Refinitiv Ibes Data (analyst estimates).